<DOC>
	<DOCNO>NCT00249405</DOCNO>
	<brief_summary>This study do determine citalopram safe effective treatment alcohol dependence . A second purpose evaluate whether alcohol dependent individual differ specific genetic marker respond differently citalopram . Citalopram drug approve U.S. Food Drug Administration ( FDA ) treatment depression . It belong category medication call selective serotonin re-uptake inhibitor SSRIs . The U.S. FDA approve citalopram treatment alcohol dependence . Therefore , use `` off-label '' study .</brief_summary>
	<brief_title>Predicting Alcoholics ' Treatment Responses Selective Serotonin Re-uptake Inhibitor ( SSRI )</brief_title>
	<detailed_description>Relapse alcoholism remain vex clinical national health problem . Efforts match alcohol dependent patient specific treatment base clinical characteristic produce mixed result . Pharmacogenetics ( study genetic influence therapeutic response drug ) offer powerful new tool match specific element individual patient 's complex genetic blueprint target pharmacotherapies individual may optimally respond . The purpose propose research apply pharmacogenetic technique predict alcohol dependent patient respond favorably trial selective serotonin re-uptake inhibitor ( SSRI ) prevention alcoholism relapse . Our central hypothesis genetic difference affect serotonin transporter function influence alcohol dependent individual 's treatment response SSRI , citalopram . To test hypothesis , perform 14-week , randomize , double blind , parallel group comparison citalopram placebo treatment seek outpatient meet DSM-IV criterion alcohol dependence . All subject receive single Motivational Interview 9 brief session manual-guided Compliance Enhancement Therapy design promote treatment adherence enhance motivation quit cut drinking . Post-treatment follow-up assessment conduct 4 , 12 24 week . Subjects ' DNA genotyped determine allelic variant promoter region serotonin transporter gene find markedly affect serotonin reuptake influence treatment responsiveness SSRIs .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>Outpatients diagnosis DSMIV alcohol dependence Not morbidly obese underweight Express desire quit cut drink duration trial Clinically significant laboratory evidence disease Have active psychological disorder alcoholism</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Clinical trial</keyword>
	<keyword>Alcoholism</keyword>
	<keyword>Alcohol</keyword>
	<keyword>Pharmacogenetics</keyword>
	<keyword>Citalopram</keyword>
	<keyword>Genotype</keyword>
	<keyword>Therapy compliance</keyword>
	<keyword>Serotonin inhibitor</keyword>
	<keyword>Alcoholism/alcohol abuse therapy</keyword>
</DOC>